～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS in Japan and Asia～

～Hidemasa的任命巩固了Aculys在日本和亚洲中枢神经系统领域的领先地位～

TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ('Aculys'), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and Representative Director, effective March 29th..

东京，2024年4月1日/PRNewswire/--Aculys Pharma，Inc.（“Aculys”）是一家专注于神经疾病创新治疗商业化的临床阶段生物制药公司，今天宣布任命Hidemasa Tanigaki为首席执行官兼代表董事，自3月29日起生效。。

Hidemasa has an outstanding track record and has been a leader in the pharmaceutical sector for over the last 30 years. Hidemasa began his journey with Takeda Pharmaceutical Company ('Takeda') in 1992 and held numerous key positions throughout his tenure with the company. After starting his career as a medical rep, he was later involved the successful launch of multiple products.

Hidemasa拥有出色的业绩记录，在过去30年中一直是制药行业的领导者。Hidemasa于1992年开始在武田制药公司（“武田”）任职，并在其任职期间担任过许多关键职位。在开始他的医疗代表职业生涯后，他后来成功推出了多种产品。

From 2015, he was global lead in Boston for the oncology business strategy. Upon his return to Japan, he served as Sales Director for Specialty Pharma and the Head of Rare Hematology, before assuming the role of President and Representative Director of Nihon Pharmaceutical Co., Ltd. in 2021. He then led the Gastrointestinal Disease Business Unit at Takeda..

从2015年起，他在波士顿担任肿瘤业务战略的全球领导者。回到日本后，他担任Specialty Pharma的销售总监和Rare Hematology的负责人，然后于2021年担任日本制药株式会社的总裁兼代表董事。然后，他领导了武田的胃肠疾病业务部门。。

Hidemasa Tanigaki, new CEO and Representative Director of Aculys, stated: 'I am thrilled to join Aculys which focuses on addressing today's drug lag/drug loss with an utmost sense of urgency. I believe the Aculys' pipeline carries great potential to transform the lives of patients. I look forward to working with the team to deliver such products to those in need as quickly as possible.'.

Aculys新任首席执行官兼代表董事Hidemasa Tanigaki表示：“我很高兴加入Aculys，它以最大的紧迫感专注于解决当今的药物滞后/药物流失问题。我相信Aculys的管道具有改变患者生活的巨大潜力。我期待着与团队合作，尽快将此类产品交付给需要的人。”。

BT Slingsby, Executive Chairperson of Aculys, added: 'The Aculys Board warmly welcomes Hidemasa as the new CEO of Aculys. We believe his impressive track record and experience in the pharmaceutical sector make him an ideal leader to take the team and assets toward commercialization. We are confident he will continue to position the Company as a leading biopharma in the field of neurological and psychiatric disorders, executing Aculys' clinical, commercial, and financial strategy.'.

Aculys执行主席BT Slingsby补充道：“Aculys董事会热烈欢迎Hidemasa担任Aculys的新任首席执行官。我们相信，他在制药行业令人印象深刻的业绩记录和经验，使他成为带领团队和资产走向商业化的理想领导者。我们相信，他将继续将公司定位为神经和精神疾病领域的领先生物制药公司，执行Aculys的“临床，商业和财务战略”。

Takeshi Takahashi will step down as the interim CEO and remain a Board Member.

高桥武（TakeshiTakahashi）将辞去临时CEO的职务，并继续担任董事会成员。

About Aculys Pharma

关于Aculys Pharma

Aculys Pharma is a clinical stage biopharmaceutical company that is pioneering ways to eliminate drug lag/drug loss in Japan, and is working to resolve social issues related to neurological and psychiatry diseases. Its corporate name was created from the philosophy of serving as a 'Catalyst to Access.' Aiming to act as a bridge for innovative medical care in the field of neuropsychiatry, Aculys Pharma develops and commercializes novel pharmaceuticals and provides innovations for better medical care to patients, their families, healthcare professionals, and society..

Aculys Pharma是一家临床阶段的生物制药公司，在日本率先消除药物滞后/药物流失，并致力于解决与神经和精神疾病相关的社会问题。它的公司名称是根据“进入的催化剂”的理念创建的Aculys Pharma旨在成为神经精神病学领域创新医疗保健的桥梁，开发和商业化新型药物，并为患者及其家人、医疗保健专业人员和社会提供更好的医疗保健创新。。

Company name: Aculys Pharma, Inc.Address: 6F, the ARGYLE aoyama, 2-14-4 Kita-Aoyama, Minato-ku,Tokyo, JapanRepresentative: Hidemasa TanigakiEstablished: Jan 2021URL: https://aculys.com/en/

公司名称：Aculys Pharma，Inc.地址：日本东京Minato ku Kita aoyama 2-14-4 ARGYLE aoyama 6F代表：Hidemasa Tanigakie成立日期：2021年1月RL：https://aculys.com/en/

SOURCE Aculys Pharma, Inc.

来源Aculys Pharma，股份有限公司。